

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

BA

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01N 1/02		A1	(11) International Publication Number: WO 00/56145
			(43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/AU00/00226		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 March 2000 (22.03.00)			
(30) Priority Data: PP 9414 23 March 1999 (23.03.99) AU PQ 4199 23 November 1999 (23.11.99) AU			
(71) Applicant (for all designated States except US): JAMES COOK UNIVERSITY [AU/AU]; Townsville, QLD 4810 (AU).			
(72) Inventor; and (75) Inventor/Applicant (for US only): DOBSON, Geoffrey, Phillip [AU/AU]; 14 Dahl Crescent, Wulguru, QLD 4811 (AU).		Published With international search report.	
(74) Agent: GRIFTH HACK; GPO Box 1285K, Melbourne, VIC 3001 (AU).			
(54) Title: ORGAN ARREST, PROTECTION AND PRESERVATION			
(57) Abstract			
<p>The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. The present invention also relates to a method for arresting, protecting and/or preserving an organ which comprises adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ. The present invention further provides a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.</p>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ORGAN ARREST, PROTECTION AND PRESERVATION

The present invention relates to a method and pharmaceutical or veterinary composition for arresting, protecting and/or preserving organs, in particular the heart during open-heart surgery, cardiovascular diagnosis or therapeutic intervention.

There are over 20,000 open-heart surgery operations each year in Australia, over 800,000 in the United States and about 1,000,000 in Europe. Of those requiring open-heart surgery, about 1.2% are neonates/infants primarily as a consequence of congenital heart disease.

The heart may be arrested for up to 3 hours during open-heart surgery. High potassium cardioplegia (in excess of 15-20 mM) has been the basis of myocardial arrest and protection for over 40 years. Currently the majority of solutions used contain high potassium including the widely used St Thomas No. 2 Hospital Solution which generally contains 110 mM NaCl, 16 mM KCl, 16 mM MgCl₂, 1.2 mM CaCl₂ and 10 mM NaHCO₃ and has a pH of about 7.8. High potassium solutions usually lead to a membrane depolarisation from about -80 to -50mV. Notwithstanding hyperkalemic solutions providing acceptable clinical outcomes, recent evidence suggests that progressive potassium induced depolarisation leads to ionic and metabolic imbalances that may be linked to myocardial stunning, ventricular arrhythmias, ischaemic injury, endothelial cell swelling, microvascular damage, cell death and loss of pump function during the reperfusion period. Infant hearts are even more prone to damage with cardioplegic arrest from high potassium than adult hearts. The major ion imbalances postulated are linked to an increased sodium influx which in turn activates the Na⁺/Ca²⁺ exchangers leading to a rise in intracellular Ca²⁺. Compensatory activation of Na⁺ and Ca²⁺ ion pumps then occur, which activate anaerobic metabolism to replenish ATP with a concomitant increase in tissue lactate and fall in tissue pH. Free radical generation and oxidative stress have also been implicated in potassium arrest and partially reversed by the administration of antioxidants. In some cases, high potassium induced

ischaemia has been reported to have damaged smooth muscle and endothelial function.

In an attempt to minimise ischaemic damage during cardioplegic arrest, an increasing number of experimental studies have employed potassium channel
5 openers instead of high potassium. Cardioprotection using nicorandil, aprikalim or pinacidil is believed to be linked to the opening of the potassium channel which leads to a hyperpolarised state, a shortening of the action potential and decreasing Ca^{2+} influx into the cell. One shortfall however is that the heart takes the same time or longer to recover with no improvement in function than
10 with high potassium cardioplegic solutions. Another limitation is that pinacidil requires a carrier due to its low solubility in aqueous solutions. The carrier routinely used is dimethyl sulphoxide (DMSO) which is controversial when used in animal or human therapy.

Most investigators, including those who advocate using potassium
15 channel openers, believe that as soon as blood flow is halted and the arrest solution administered, ischaemia occurs and progressively increases with time. To reduce the likelihood of damage, we sought a cardioplegic solution that would place the heart in a reversible hypometabolic state analogous to the tissues of a hibernating turtle, a hummingbird in torpor or an aestivating desert
20 frog. When these animals drop their metabolic rate (some by over 90%), their tissues do not become progressively ischaemic but remain in a down-regulated steady state where supply and demand are matched. An ideal cardioplegic solution should produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The heart should accumulate low tissue lactate,
25 utilise little glycogen, show minimal changes in high-energy phosphates, cytosolic redox (NAD/NADH) and the bioenergetic phosphorylation (ATP/ADP Pi) ratio and free energy of ATP. There should be little or no change in cytosolic pH or free magnesium, minimal water shifts between the intracellular and extracellular phases, and no major ultrastructural damage to organelles such as
30 the mitochondria. The ideal cardioplegic solution should produce 100% functional recovery with no ventricular arrhythmia, cytosolic calcium overload

or other pump abnormalities. There is no cardioplegic solution currently available which fulfils all these requirements. We have now found that the heart can be better protected during arrest and recovery by using the potassium channel opener adenosine and the local anaesthetic lignocaine.

5 The action of adenosine is controversial. Adenosine has been shown to increase coronary blood flow, hyperpolarise the cell membrane and act as a preconditioning agent via the ATP-sensitive potassium channel and adenosine related pathways including adenosine receptors notably the A1 receptor. Adenosine is also known to improve myocardial recovery as an adjunct to high
10 potassium cardioplegia. Furthermore, adenosine can be used as a pretreatment (whether or not it is present in the arresting solution) to reduce lethal injury. In one study, adenosine was shown to rival potassium arrest solutions and more recently in blood cardioplegia, it prevented post-ischaemic dysfunction in ischaemically injured hearts. Adenosine is sometimes added as an adjunct to
15 potassium cardioplegia.

 Lignocaine is a local anaesthetic which blocks sodium fast channels and has antiarrhythmic properties by reducing the magnitude of inward sodium current. The accompanying shortening of the action potential is thought to directly reduce calcium entry into the cell via Ca^{2+} selective channels and
20 $\text{Na}^+/\text{Ca}^{2+}$ exchange. Recent reports also implicate lignocaine with the scavenging of free radicals such as hydroxyl and singlet oxygen in the heart during reperfusion. Associated with this scavenging function, lignocaine may also inhibit phospholipase activity and minimise membrane degradation during ischaemia. Lignocaine has also been shown to have a myocardial protective
25 effect and in one study was found to be superior to high potassium solutions. However, our experiments show that lignocaine alone at 0.5, 1.0 and 1.5 mM gave highly variable functional recoveries using the isolated working rat heart.

 According to one aspect of the present invention there is provided a method for arresting, protecting and/or preserving an organ which includes
30 administering effective amounts of (i) a potassium channel opener or agonist

and/or an adenosine receptor agonist and (ii) a local anaesthetic to a subject in need thereof.

According to another aspect of the present invention there is provided the use of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic in the manufacture of a medicament for
5 arresting, protecting and/or preserving an organ.

The present invention also provides (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic for use in arresting, protecting and/or preserving an organ.

10 According to a further aspect of the present invention there is provided a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.

While the present invention is particularly advantageous in arresting,
15 protecting and/or preserving an organ while it is intact in the body of the subject, it will be appreciated that it may also be used to arrest, protect and/or preserve isolated organs.

Thus, the present invention still further provides a method for arresting, protecting and/or preserving an organ which includes adding a composition
20 which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ.

The term "adding" is used herein in its broadest sense to refer to any methods of exposing the organ to the composition of the present invention, for example, bathing, perfusing or pumping via various routes.

25 The term "organ" is used herein in its broadest sense and refers to any part of the body exercising a specific function including tissues and cells or parts thereof, for example, cell lines or organelle preparations. Other examples include circulatory organs such as the heart, respiratory organs such as the lungs, urinary organs such as the kidneys or bladder, digestive organs such as the stomach, liver, pancreas or spleen; reproductive organs such as the scrotum,
30 testis, ovaries or uterus, neurological organs such as the brain, germ cells such

as spermatozoa or ovum and somatic cells such as skin cells, heart cells i.e., myocytes, nerve cells, brain cells or kidney cells.

The method of the present invention is particularly useful in arresting, protecting and/or preserving the heart during open-heart surgery including heart transplants. Other applications include reducing heart damage before, during or following cardiovascular intervention which may include a heart attack, angioplasty or angiography. For example, the composition could be administered to subjects who have suffered or are developing a heart attack and used at the time of administration of blood clot-busting drugs such as streptokinase. As the clot is dissolved, the presence of the composition may protect the heart from further injury such as reperfusion injury. The composition may be particularly effective as a cardioprotectant in those portions of the heart that have been starved of normal flow, nutrients and/or oxygen for different periods of time. For example, the composition may be used to treat heart ischaemia which could be pre-existing or induced by cardiovascular intervention.

Thus, the present invention also provides a cardioplegic or cardioprotectant composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.

The potassium channel openers or agonists may be selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benzimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIC (Q-type), cyproheptadine HCl, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HCl (L-type), flodipine, flunarizine HCl ($\text{Ca}^{2+}/\text{Na}^{+}$), fluspirilene (L-type), HA-1077 2HCl(1-(5 isoquinoliny) sulphonyl) homo piperazine.HCl), isradipine, loperamide HCl, manoalide (Ca^{2+} release

inhibitor), nifedipine HCl (L-type), nifedipine (L-type), nifedipine HCl (L-type), nimodipine (L-type), nitrendipine (L-type), pimozone (L- and T-type), ruthenium red, ryanodine (SR channels), tetrodotoxin, verapamil HCl (L-type), methoxy-verapamil HCl (L-type), YS-035 HCl (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethanamine HCl) and AV blockers such as verapamil and adenosine. It will be appreciated that this list includes calcium antagonists as potassium channel openers are indirect calcium antagonists.

Adenosine is particularly preferred as it is capable of opening the potassium channel, hyperpolarising the cell, depressing metabolic function, possibly protecting endothelial cells, enhancing preconditioning of tissue and protecting from ischaemia or damage. Adenosine is also an indirect calcium antagonist, vasodilator, antiarrhythmic, antiadrenergic, free radical scavenger, arresting agent, anti-inflammatory agent (attenuates neutrophil activation), metabolic agent and possible nitric oxide donor.

In a preferred embodiment, the present invention provides a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of adenosine and a local anaesthetic to a subject in need thereof.

Suitable adenosine receptor agonists include N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl)ethyl]adenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-ribofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methylpropyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).

The local anaesthetic can be selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mepivacaine and Class 1B antiarrhythmic agents such as

lignocaine or derivatives thereof, for example, QX-314. Lignocaine is preferred as it is capable of acting as a local anaesthetic probably by blocking sodium fast channels, depressing metabolic function, lowering free cytosolic calcium, protecting against enzyme release from cells, possibly protecting endothelial cells and protecting against myofilament damage. Lignocaine is also a free radical scavenger and an antiarrhythmic.

As lignocaine acts by blocking sodium fast channels, it will be appreciated that other sodium channel blockers could be used instead of or in combination with the local anaesthetic in the method and composition of the present invention. Examples of suitable sodium channel blockers include venoms such as tetrodotoxin.

Thus, in a particularly preferred embodiment there is provided a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of adenosine and lignocaine to a subject in need thereof.

In another preferred embodiment there is provided a pharmaceutical or veterinary composition which includes effective amounts of adenosine and lignocaine.

For ease of reference, the "potassium channel opener or agonist and/or adenosine receptor agonist" and the "local anaesthetic" will hereinafter be referred to as the "active ingredients".

The method of the present invention involves the administration of effective amounts of the active ingredients for a time and under conditions sufficient for the organ to be arrested, protected and/or preserved. The active ingredients may be administered separately, sequentially or simultaneously and in a single dose or series of doses.

The subject may be a human or an animal such as a livestock animal (e.g. sheep, cow or horse), laboratory test animal (e.g. mouse, rabbit or guinea pig) or a companion animal (e.g. dog or cat), particularly an animal of economic importance.

It will be appreciated that the amounts of active ingredients present in the composition will depend on the nature of the subject, the type of organ being arrested, protected and/or preserved and the proposed application. In the case of a human subject requiring heart arrest during open-heart surgery, the concentration of adenosine is preferably about 0.001 to about 20mM, more preferably about 0.01 to about 10mM, most preferably about 0.05 to about 5mM and the concentration of lignocaine is preferably about 0.001 to about 20mM, more preferably about 0.01 to about 10mM, most preferably about 0.05 to about 5mM. In the case of a human subject requiring treatment before, during or following a heart attack or cardiovascular intervention, the preferred concentrations of adenosine and lignocaine are set out in the table below.

Site of Injection	Type/Units	Adenosine	
Lignocaine			
Intravenous	Infusion mg/min/kg	1. 0.001-10	1. 0.0001-20
		2. 0.01-5	2. 0.01-10
		3. 0.01-1	3. 0.5-3
Intravenous	Bolus mg/kg	1. 0.0001-100	1. 0.001-1000
		2. 0.001-10	2. 0.01-100
Intracoronary	Infusion mg/min (per heart)	1. 0.0001-100	1. 0.005-50
		2. 0.001-1	2. 0.005-5
		3. 0.01-0.5	3. 0.05-2.5
Intracoronary	Bolus µg (per heart)	1. 0.001-1000	1. 0.01-10,000
		2. 0.1-100	2. 1-1000
		3. 1-20	3. 10-200

1 = preferably

15 2 = more preferably

3 = most preferably

The active ingredients may be administered by any suitable route including oral, implant, rectal, inhalation or insufflation (through the mouth or nose), topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intrasternal and intradermal). Preferably, administration in open-heart surgery or cardiovascular intervention applications will be achieved by mixing the active ingredients with the blood of the subject or subjects having a similar blood type. The active ingredients then enter the coronary circulation generally via the aorta. Arrest may also be achieved by either continuous or intermittent delivery. For example, heart arrest may occur by either continuous or intermittent perfusion retrograde through the aorta in the Langendorff mode. However, it will be appreciated that the preferred route will vary with the condition and age of the subject and the chosen active ingredients.

The composition of the present invention is highly beneficial at about 15°C to about 37°C, preferably about 20°C to about 37°C, where longer arrest times using St Thomas No. 2 solution can only be achieved when the temperature is lowered, for example, down to about 4°C.

While it is possible for one or both of the active ingredients to be administered alone, it is preferable to administer one or both of them together with one or more pharmaceutically acceptable carriers, diluents adjuvants and/or excipients. Each carrier, diluent, adjuvant and/or excipient must be pharmaceutically "acceptable" in the sense of being compatible with the other ingredients of the composition and not injurious to the subject. The compositions may conveniently be presented in unit dosage form and may be prepared by methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. Preferably, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers, diluents, adjuvants and/or excipients.

The present invention also extends to a pharmaceutical or veterinary composition which includes the active ingredients and a pharmaceutically or veterinarily acceptable carrier, diluent, adjuvant and/or excipient.

Compositions of the present invention suitable for oral administration
5 may be presented as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredients may also be presented as a bolus, electuary or paste.

10 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl
15 cellulose), fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate), lubricants (e.g. magnesium stearate, talc or silica), inert diluent, preservative, disintegrant (e.g. magnesium stearate, talc or silica), inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface-active or dispersing
20 agents. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the
25 desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

Liquid preparations for administration prior to arresting, protecting and/or preserving the organ may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with
30 water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives

such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid); and energy sources (e.g. carbohydrates such as glucose, fats such as palmitate or amino acid).

Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavoured basis, usually sucrose and acacia or tragacanth gum; pastilles comprising the active ingredients in an inert basis such as gelatin and glycerin, or sucrose and acacia gum; and mouthwashes comprising the active ingredients in a suitable liquid carrier.

For topical application for the skin, the active ingredients may be in the form of a cream, ointment, jelly, solution or suspension.

For topical application to the eye, the active ingredients may be in the form of a solution or suspension in a suitable sterile aqueous or non-aqueous vehicle. Additives, for instance buffers, preservatives including bactericidal and fungicidal agents, such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorohexidine and thickening agents such as hypromellose may also be included.

The active ingredients may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the active ingredients may be formulated with suitable polymeric or hydrophobic materials (e.g. as an emulsion in an acceptable oil or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt).

Compositions for rectal administration may be presented as a suppository or retention enema with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the active ingredients. Such excipients include cocoa butter or a salicylate.

For intranasal and pulmonary administration, the active ingredients may be formulated as solutions or suspensions for administration via a suitable metered or unit dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.

- 5 Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

10 Compositions suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended subject; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose sealed
15 containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described

- 20 When the composition is for veterinary use it may be prepared, for example, by methods that are conventional in the art. Examples of such veterinary compositions include those adapted for:

- (a) oral administration, external application, for example drenches (e.g. aqueous or non-aqueous solutions or suspensions); tablets or boluses;
25 powders, granules or pellets for admixture with feedstuffs; pastes for application to the tongue;
- (b) parenteral administration for example by subcutaneous, intramuscular or intravenous injection, e.g. as a sterile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution
30 is introduced into the udder via the teat;

(c) topical application, e.g. as a cream, ointment or spray applied to the skin;
or

(d) intravaginally, e.g. as a pessary, cream or foam.

It should be understood that in addition to the ingredients particularly
5 mentioned above, the compositions of this invention may include other agents
conventional in the art having regard to the type of composition in question, for
example, those suitable for oral administration may include such further agents
as binders, sweeteners, thickeners, flavouring agents, disintegrating agents,
coating agents, preservatives, lubricants and/or time delay agents.

10 Suitable sweeteners include sucrose, lactose, glucose, aspartame or
saccharin. Suitable disintegrating agents include corn starch, methylcellulose,
polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable
flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or
raspberry flavouring. Suitable coating agents include polymers or copolymers
15 of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols,
zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin
E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium
bisulphite. Suitable lubricants include magnesium stearate, steric acid, sodium
oleate, sodium chloride or talc. Suitable time delay agents include glyceryl
20 monostearate or glyceryl distearate.

A preferred pharmaceutically acceptable carrier is a buffer having a pH
of about 6 to about 9, preferably about 7, more preferably about 7.4 and/or low
concentrations of potassium, for example, up to about 10mM, more preferably
about 2 to about 8 mM, most preferably about 4 to about 6mM. Suitable buffers
25 include Krebs-Henseleit which generally contains 10mM glucose, 117 mM
NaCl, 5.9 mM KCl, 25 mM NaHCO₃, 1.2 mM NaH₂PO₄, 1.12 mM CaCl₂ (free
Ca²⁺=1.07mM) and 0.512 mM MgCl₂ (free Mg²⁺=0.5mM), St. Thomas No. 2
solution, Tyrodes solution which generally contains 10mM glucose, 126 mM
NaCl, 5.4 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 0.33 mM NaH₂PO₄ and 10 mM
30 HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethane sulphonic acid]), Fremes
solution, Hartmanns solution which generally contains 129 NaCl, 5 mM KCl, 2

mM CaCl_2 and 29 mM lactate and Ringers-Lactate. One advantage of using low potassium is that it renders the present composition less injurious to the subject, in particular pediatric subjects such as neonates/infants. High potassium has been linked to an accumulation of calcium which may be associated with irregular heart beats during recovery, heart damage and cell swelling. Neonates/infants are even more susceptible than adults to high potassium damage during cardiac arrest. After surgery for defects a neonate/infant's heart may not return to normal for many days, sometimes requiring intensive therapy or life support. It is also advantageous to use carriers having low concentrations of magnesium, such as, for example up to about 2.5mM, but it will be appreciated that high concentrations of magnesium, for example up to about 20mM, can be used if desired without substantially effecting the activity of the composition.

In a further preferred embodiment the present invention provides a pharmaceutical or veterinary composition which includes adenosine, lignocaine and a pharmaceutically acceptable carrier which contains up to about 10mM potassium.

In a still further preferred embodiment, the present invention provides a pharmaceutical or veterinary composition which includes adenosine, lignocaine and Krebs-Henseleit buffer.

The composition may also advantageously be presented in the form of a kit in which the active ingredients are held separately for separate, sequential or simultaneous administration.

It will be appreciated that the composition of the present invention may also include and/or be used in combination with known medicaments depending on the proposed application. For instance, medicaments which substantially prevent the breakdown of adenosine in the blood such as nucleoside transport inhibitors, for example, dipyridamole could be used as additives in the composition of the present invention. The half life of adenosine in the blood is about 10 seconds so the presence of a medicament to substantially prevent its breakdown will maximise the effect of the composition of the present invention.

Dipyridamole could advantageously be included in concentrations from about 0.1nM to about 10 mM and has major advantages with respect to cardioprotection. Dipyridamole may supplement the actions of adenosine by inhibiting adenosine transport which increases vasodilation. This could be particularly important when the composition is administered intermittently.

Other examples of medicaments include clot-busting drugs such as streptokinase. As discussed earlier, the composition could be administered at the time of administration of streptokinase in subjects who have suffered or are developing a heart attack.

The invention will now be described with reference to the following examples. These examples are not to be construed as limiting in any way.

In the example, reference will be made to the accompanying drawings in which:

Figure 1 is a graph of aortic flow vs time comparing hearts arrested using 100µM adenosine and 0.5 mM lignocaine in Krebs-Henseleit and St. Thomas Hospital No. 2 solution;

Figure 2 is six graphs showing heart, rate systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 30 mins intermittent ischaemia;

Figure 3 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 2hrs intermittent ischaemia;

Figure 4 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 4hrs intermittent ischaemia;

Figure 5 is a bar graph providing a summary of the results of Figures 2 to 4;

Figure 6 is six graphs showing heart rate, systolic pressure, aortic flow, coronary flow, MV02 and rate pressure product recovery from 2hrs of intermittent ischaemia using neonate rat hearts;

Figure 7 is four graphs showing 20min ischaemia in rat heart *in vivo* following coronary artery ligation with no adenosine-lignocaine infusion;

Figure 8 is four graphs showing 20min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (6.3mg/ml) and
5 lignocaine (12.6mg/ml) at 1ml/hour/300g rat ;

Figure 9 is a graph showing 30min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (6.3mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 10 is four graphs showing 20min ischaemia in rat heart *in vivo*
10 following coronary artery ligation when infused with adenosine (3.15mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 11 is four graphs showing 30min ischaemia in rat heart *in vivo* following coronary artery ligation when infused with adenosine (1.6mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 12 is a graph showing 30min ischaemia in rat heart *in vivo*
15 following coronary artery ligation when infused with adenosine (1.6mg/ml) and lignocaine (12.6mg/ml) at 1ml/hour/300g rat;

Figure 13 is two graphs showing the change in ATP and PCr versus time of ischaemia during a heart attack *in vivo* with and without the presence of AL;

Figure 14 is two graphs showing the change in lactate and myocardial pH
20 versus time of ischaemia during a heart attack *in vivo* with and without the presence of AL; and

Figure 15 is two graphs showing the change in glycogen and rate pressure product versus time of ischaemia during a heart attack *in vivo* with and
25 without the presence of AL.

In the examples, "AL" refers to compositions containing adenosine and lignocaine.

EXAMPLE 1

30 This example compares the effects of adenosine (100 μ M) cardioplegia with hyperkalemic St. Thomas Hospital No. 2 solution (16 mM K⁺) on

functional recovery after a period of global ischaemia using continuous perfusion.

Hearts from male 450g Sprague-Dawley rats (n=19) were perfused for 30 minutes in the working mode (preload 7.5 mmHg; afterload 100 mmHg) with
5 Krebs-Henseleit pH 7.4 buffer at 37°C. Hearts were then arrested in a retrograde mode at a constant pressure of 70 mmHg with either (i) a solution containing 100 µM adenosine and 0.5 mM lignocaine in filtered Krebs-Henseleit (10 mM glucose, pH 7.6 – 7.8 @ 37°C) (n=11) or (ii) St. Thomas No
10 2 solution (0.2 micron filter) (n=8). Following either 30 minutes or 4hrs of arrest, the hearts were switched back to normal antegrade perfusion with Krebs-Henseleit pH 7.4 @ 37°C. Heart rate, coronary flow, aortic flow, aortic pressure and oxygen consumption were monitored. Statistical significance was assessed using a Student t-Test.

15 Results

Hearts arrested for 30 minutes using adenosine cardioplegia achieved quiescence in half the time compared to St. Thomas No. 2 solution (30 vs 77 seconds, $p < 0.0001$). During arrest under a constant perfusion pressure, coronary blood flow was 30% greater using adenosine cardioplegia ($p < 0.05$).
20 Faster recoveries were found in AL hearts in aortic pressure, aortic flow and cardiac output during reperfusion. After 5 min into reperfusion, the heart rate, aortic pressures, aortic flow, coronary flow, cardiac output and O₂ consumption were higher in the AL hearts (Table 1). Higher aortic flows were also found at 15, 25 and 35 min against a perfusion head of 100 mmHg (Figure 1).

Table 1

Comparison between adenosine and lignocaine cardioplegia and St Thomas No 2 Hospital solution after 30 min Normothermic Continuous Arrest in the working rat heart (37°C)

Parameter	Adenosine and lignocaine (n=11)			Thomas No 2 Solution (n=12)		
	30 ± 2 sec			77 ± 6 sec		
	Control	5 min	% Control	Control	5 min	% Control
Heart (bpm)	292 ± 9	213 ± 8	73%	285 ± 14	150 ± 35	53%
Systolic pressure (mmHg)	122 ± 3	126 ± 4	103%	126 ± 3	88 ± 14	70%*
Diastolic Pressure (mmHg)	76 ± 1	74 ± 1.3	97%	78.5 ± 1.2	59 ± 8.5	75%
Aortic flow (ml/min)	35.6 ± 3	24 ± 4	67%	31.5 ± 4.1	9.96 ± 2.8	32%*
Coronary flow (ml/min)	16.4 ± 0.7	13.6 ± 0.9	83%	17.4 ± 0.74	10 ± 1.9	57%
Cardiac Output (ml/min)	52 ± 3	37.2 ± 4.7	72%	50 ± 4	20 ± 4.5	40%*
O ₂ consumption (μmol/min/g wet wt)	6.97 ± 0.28	5.39 ± 0.38	77%	7.28 ± 0.30	4.14 ± 0.5	57%

Control values are taken 5 min prior to the 30 min arrest protocol. * Significant P<0.05

In terms of functional parameters, 100 μ M adenosine and 0.5 mM lignocaine cardioplegia lead to shorter arrest times and an enhanced recovery profile compared to the St. Thomas Hospital No. 2 solution.

The results for hearts arrest for 4hrs are shown in Table 2 below.

Table 2

Comparison of functional Recovery of S-D Rat Hearts After 30min Continuous Cardioplegia With Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No. 2

19

	n	Heart Rate (bpm)	Stable Perfusion Period					Arrest
			Systolic Pressure (mmHg)	Coronary Flow (ml/min)	Aortic Flow (ml/min)	Cardiac Output (ml/min)	MV02 (μ mol/min/g)	
Adenosine + Lignocaine	7	292.18 \pm 8.82	122.38 \pm 3.58	16.44 \pm 1.07	35.66 \pm 3.33	52 \pm 2.73	6.97 \pm 0.28	30 min Cardoplegic Arrest with Constant Perfusion Delivered at 70mmHg
Cardioplegia	%	100	100	100	100	100	100	
St Thomas Hospital	10	2.85 \pm 13.48	128.08 \pm 3.14	17.4 \pm 0.74	31.53 \pm 4.09	48.93 \pm 4.15	7.28 \pm 0.3	
Solution No 2	%	100	100	100	100	100	100	

Table 2 cont.

After 5min Reperfusion						
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Coronary Flow (ml/min)	Aortic Flow (ml/min)	Cardiac Output (ml/min)
Adenosine	7	212.91	126.09	13.6	23.64	37.24
+ Lignocaine		± 7.62	± 4.15	± 0.92	± 4.09	± 4.73
Cardioplegia	%	73	103	83	66	72
St Thomas	10	150.36	88.08	10.09	9.96	20.06
Hospital		± 34.45	± 14.21	± 1.93	± 2.83	± 4.49
Solution No. 2	%	53	70	57	32	40
						57

Table 2 cont.

After 15min Reperfusion							
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Coronary Flow (ml/min)	Aortic Flow (ml/min)	Cardiac Output (ml/min)	MV02 (μ mol/min/g)
Adenosine	7	262.18	114.91	12.55	25.07	37.82	5.89
+ Lignocaine		± 10.36	± 4.18	± 1.03	± 3.08	± 3.89	± 0.32
Cardioplegia	%	90	94	76	71	72	86
St Thomas	10	257.09	118.82	15.05	16.18	31.24	6.1
Hospital		± 14.81	± 3.81	± 1.24	± 2.95	± 3.73	± 0.45
Solution No. 2	%	90	94	86	51	64	84

Table 2 cont.

After 25min Reperfusion							
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Coronary Flow (ml/min)	Aortic Flow (ml/min)	Cardiac Output (ml/min)	MV02 (μ mol/min/g)
Adenosine	7	253.54	118.4	14.08	30.52	44.8	8.06
+ Lignocaine		± 28.47	± 3.58	± 0.75	± 2.73	± 3	± 0.31
Cardioplegia	%	87	97	86	86	86	87
St Thomas	10	266.91	118.09	15.05	23.11	38.16	6.6
Hospital		± 15.16	± 3.43	± 1.04	± 3.94	± 4.47	± 0.48
Solution No. 2	%	94	94	86	73	78	91

Table 2 cont.

After 35min Reperfusion							
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Coronary Flow (ml/min)	Aortic Flow (ml/min)	Cardiac Output (ml/min)	MV02 (μ mol/min/g)
Adenosine	7	283.83	118.88	14.2	32.13	46.33	6.54
+ Lignocaine		± 11.74	± 4.62	± 0.68	± 2.94	± 3.43	± 0.09
Cardioplegia	%	97	97	88	90	89	94
St Thomas	10	271.27	120.45	15.38	25.35	40.74	6.74
Hospital		± 14.04	± 3.11	± 1.37	± 4.03	± 4.4	± 0.48
Solution No. 2	%	96	96	88	80	89	96

EXAMPLE 2

Adult Wistar rats (350g) were prepared using the method described in Example 2 and then subjected to intermittent perfusion as discussed below.

Intermittent retrograde perfusion was performed under a constant pressure head of 70mmHg after hearts were switched back from the working mode to the Lagendorff mode. After stabilisation, the hearts were arrested using 50ml of either adenosine plus lignocaine cardioplegia or St Thomas Hospital No 2 solution. The aorta was then cross-clamped and the heart left to sit arrested for 20min (except in 30 min intermittent arrest protocol), after which the clamp was released and 2min of arrest solution delivered from a pressure head of 70 mmHg. The clamp was replaced and this procedure continued for up to 30mins, 2hrs and 4hrs at 37°C.

Intermittent cardioplegic delivery is the method commonly used clinically in contrast to continuous perfusion in Example 1. During Intermittent arrest, the aorta of the subject is clamped and the arrest solution administered. After a few minutes, the heart is arrested and cardioplegia delivery stopped. The heart remains motionless to permit surgery. The arrest solution is administered again every 30 min for few minutes to maintain the heart in the arrested state to preserve and protect the heart muscle. Between these times, the heart muscle slowly becomes ischaemic indicated by the production of lactate and fall in muscle pH. For this reason, intermittent perfusion delivery is often called intermittent ischaemic arrest. The results are shown in Tables 3 to 7 below and Figures 2 to 5.

30min Ischaemic Arrest At 37°C

Table 3 and Figure 2 show that A-L arrests in half the time of St Thomas solution 21s (n=7) vs 53s (n=10). All hearts returned function to the same level following reperfusion (no significant difference between groups).

Table 3

**Characteristics of Adult Heart 30min Intermittent Arrest* Achieved by
Adenosine/Lignocaine Cardioplegia and St Thomas Hospital Solution No. 2
*(2min cardioplegia pulse after 15 min periods of aortic clamping)**

	Adenosine/Lignocaine Cardioplegia (n=7)	St Thomas Hospital Solution No. 2 (n=10)	P
Arrest Time (s)	21.43 ±3.92	52.78 ±5.65	p<0.01
Time to First Contraction	147.14	133.67	ns
Following Reperfusion (s)	±14.95	±31.44	
Time to Recover 100mmHg	302.14 ±21.87	309.44 ±30.15	ns

Table 4

Comparison of functional Recovery of Rat Hearts after 30min Intermittent Ischaemia* With Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No 2

Stable Perfusion Period									
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)	Arrest
Adenosine + Lignocaine Cardioplegia	7	245.38 \pm 11.01	128.23 \pm 2.83	34.33 \pm 3.64	21.64 \pm 2.02	58.29 \pm 4.63	31504 \pm 1651	6.31 \pm 0.65	30min Ischaemia Arrest with Cardioplegia Delivered at 15min
St Thomas Hospital Solution No 2	10	276.74 \pm 11.87	123.64 \pm 1.30	32.78 \pm 2.09	19.38 \pm 1.62	55.36 \pm 2.59	34090 \pm 1111	5.97 \pm 0.56	
		100	100	100	100	100	100	100	

Table 4 cont.

After 5min Reperfusion									
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (unmol/min/g)	
Adenosine	7	180.48	132.79	22.06	*22.15	47.59	24074	6.81	27
+ Lignocaine		± 26.83	± 6.65	± 4.48	± 2.20	± 2.70	± 3330	± 0.97	
Cardioplegia		74	104	64	102	82	76	108	
St Thomas	10	135.94	81.82	19.04	*13.48	34.61	23281	5.02	
Hospital		± 32.71	± 15.94	± 4.69	± 2.47	± 6.96	± 4069	± 0.79	
Solution No 2	49			58	70	63	68	84	

*Statistically Significant Difference Using Students TTEST (p<0.05)

Table 4 cont.

After 15min Reperfusion									
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)	Arrest
Adenosine	7	225.31	126.17	29.21	17.14	48.99	28228	5.03	
+ Lignocaine		± 19.17	± 2.88	± 3.20	± 1.81	± 3.76	± 2015	± 0.49	
Cardioplegia	92	98	98	85	79	84	90	80	
St Thomas	10	255.88	121.56	24.84	17.00	45.07	31131	5.41	
Hospital		± 9.69	± 1.32	± 2.36	± 1.64	± 2.47	± 1267	± 0.53	
Solution No 2	92	98	98	76	88	81	91	91	

Table 4 cont.

After 30min Reperfusion								
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	7	236.94	124.84	29.60	16.49	49.09	29403	5.42
+ Lignocaine		± 13.75	± 2.61	± 2.83	± 1.51	± 1.95	± 1231	± 0.70
Cardioplegia		97	97	86	76	84	93	86
St Thomas	10	255.17	122.16	22.26	17.08	42.41	31154	5.26
Hospital		± 12.29	± 1.62	± 3.32	± 1.20	± 3.28	± 1464	± 0.38
Solution No 2		92	99	68	88	77	91	88

Table 4 cont.

After 60min Reperfusion								
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	7	244.97	119.80	22.42	15.52	41.53	29269	5.25
+ Lignocaine		± 11.48	± 2.95	± 3.48	± 0.49	± 2.78	± 1240	± 0.55
Cardioplegia		100	93	65	72	71	93	83
St Thomas	10	258.16	117.57	17.01	15.46	35.89	30392	5.08
Hospital		± 13.88	± 1.68	± 3.08	± 1.21	± 3.46	± 1727	± 0.33
Solution No 2		93	95	52	80	65	89	85

2hr Ischaemic Arrest At 37°C

Table 5 and Figure 3 show that A-L arrests in half the time of St Thomas solution 33s (n=7) vs 81s (n=8). 4 out of 8 hearts arrested with St Thomas did not recover. All A-L hearts survived (n=7). St Thomas hearts which recovered (n=4) had 50-90% aortic flow, 70-120% heart rate and 90-100% systolic pressure. A-L hearts recovered 80% aortic flow, 95% heart rate and 95-100% systolic pressure.

10 Table 5

Characteristics of Adult Rat Heart 2hr Ischaemic Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital Solution No. 2
***(2min Cardioplegia pulse repeated after 20 min of aortic clamping)**

	n	Adenosine/ Lignocaine Cardioplegia	n	St Thomas Hospital Solution No. 2	p
Arrest Time(s)	7	33 ± 5	8	81 ± 8	0.0003
Time to First Contraction following Reperfusion(s)	7	360 ± 19	4	260 ± 95	NS
Time to Recover 100mmHg and Achieve Aortic flow(s)	7	541 ± 46	4	2400 ± 3261	NS
Percentage of Hearts to Survive Reperfusion		100		50	

4hr Ischaemic Arrest At 37°C

Tables 6 and 7 and Figure 4 show A-L arrests in half the time of St Thomas solution (26s (n=9) vs 78s (n=7)). 6 out of 7 hearts arrested with St Thomas did not recover. All A-L hearts survived (n=9). The single St Thomas heart which recovered had 40% aortic flow, 80% heart rate and 90% systolic pressure. A-L hearts recovered 70% aortic flow, 90% heart rate and 95-100% systolic pressure.

10 Table 6

Characteristics of Adult Rat Heart 4hr Ischaemic Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital Solution No. 2
***(2min cardioplegia pulse repeated after 20 min of aortic clamping)**

	Adenosine/ Lignocaine Cardioplegia	St Thomas Hospital Solution No. 2	p
Arrest Time(s)	26.44 ± 2.77 (n=9)	77.86 ± 10 (n=7)	<0.001
Time to First Contraction following Reperfusion(s)	401.67 28.48 (n=9)	390.00 (n=1)	
Time to Recover 100mmHg and Achieve Aortic flow(s)	549.22 40.68 (n=9)	480.00 (n=1)	
Percentage of Hearts to Survive Reperfusion	100 (n=9)	14 (n=1)	<0.0001

Table 7

Comparison of function Recover of Rat Hearts After 4hr Intermittent Ischaemic Arrest with Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No. 2

Stable Perfusion Period									
n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)	Arrest	
Adenosine + Lignocaine Cardioplegia	9	275.33 \pm 12.91	118.44 \pm 3.50	36.47 \pm 1.65	16.28 \pm 1.03	53.88 \pm 1.73	32338 \pm 1084	6.71 \pm 0.45	4hr Ischaemic Arrest with 2min Cardioplegia
St Thomas Hospital Solution No. 2	7 (n=1)	259.21 \pm 12.84	121.57 \pm 2.42	41.23 \pm 4.18	16.03 \pm 1.26	57.26 \pm 5.30	31508 \pm 1672	7.64 \pm 0.24	Delivered Every 20min
		270	117.00	51	19.8	70.8	315900	7.28	

Table 7 cont.

After 15min Reperfusion								
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	9	229.89	110.89	19.81	13.92	36.49	25327	5.94
+ Lignocaine		± 16.10	± 1.86	± 3.56	± 1.53	± 4.13	± 1555	± 0.69
Cardioplegia		% 83	94	54	86	68	78	89
St Thomas	1	220.00	100	18.60	16.20	36.40	22000	5.303
Hospital		% 81	85	36	82	51	70	73
Solution No. 2								

Table 7 cont.

After 30min Reperfusion								
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	9	239.444	113.00	24.62	11.53	39.44	26684	4.946
+ Lignocaine		± 18.7165	± 3.07	± 2.917	± 1.001	± 4.259	± 1669	± 0.443
Cardioplegia		% 87	95	68	71	73	83	74
St Thomas	1	220	105.00	16.8	20.4	39.2	23100	5.303
Hospital		% 81	90	33	103	55	73	73
Solution No. 2								

Table 7 cont.

After 60min Reperfusion								
	n	Heart Rate (bpm)	Systolic Pressure (mmHg)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	9	249.22	111.89	25.58	11.39	40.63	27570	5.04
+ Lignocaine		± 17.19	± 3.29	± 3.26	± 1.32	± 4.72	± 1577	± 0.49
Cardioplegia		% 91	94	70	70	75	85	75
St Thomas	1	250.00	102.00	14.40	18.00	34.40	25500	6.29
Hospital		% 93	87	28	91	49	81	86
Solution No. 2								

Figure 5 is a summary of the results of Figures 2 to 4 which shows hearts arrested with AL solution all survived after 30 min ischaemic intermittent arrest (n=7), 2 hrs intermittent arrest (n=7) and 4 hrs of intermittent arrest (n=9). In contrast, while all hearts arrested with St Thomas solution survived after 30 min (n=10), only 50% (4 out of 8 tested) and 14% survived (1 out of 7) tested. In addition, two hearts have been arrested with AL successfully for 6 hrs (Figure 5).

Figures 2 to 4 show the functional properties (heart rate, systolic pressure, aortic flow, coronary flow, oxygen consumption and rate-pressure product) during 60 min after 0.5 hr arrest (Figure 2) 2hr arrest (Figure 3) and 4 hrs arrest (Figure 4). In all cases, hearts arrested with AL solution had higher functional recovery parameters. After 0.5 hr arrest, these differences were not significant except for aortic flow recover in hearts receiving AL arrest solution. Aortic flow against a pressure head of 70 mmHg recovered to 90% of control values at 30 min compared to 65% in St Thomas hearts. After 2 hr intermittent ischaemic arrest the differences in functional recover are more striking. In AL arrested hearts, heart rate and systolic pressure recovered to nearly 100% of control values whereas St. Thomas hearts only recovered 40-50%. Aortic flow, coronary flow, oxygen consumption and rate-pressure product recovered 80% and above the controls in AL hearts and only 20-40% in St Thomas hearts. After 4 hr arrest the differences were even grater with only 1 out of 7 St Thomas hearts recovering. All AL hearts recovered after 4 hr arrest with similar recovery functional profiles described above for 2 hr. It can be concluded that AL arrest provides superior protection during 2 and 4 hr arrest and recovery in adult hearts.

EXAMPLE 3

Neonatal/infant rat hearts (using 50-70g 20 day old rats) were prepared using the intermittent perfusion technique for 2hr at 37°C described in Example 2 except the pressure head of delivery and afterload was reduced to 50mmHg. The results shown in Tables 8 and 9 below and Figure 6 show that A-L arrests

in a third of the time of St Thomas solution 19s (n=7) vs 66s (n=7). 3 out of 7 hearts arrest with St Thomas did not recover. All A-L hearts survived (n=7) with 80% aortic flow. The St Thomas hearts which recovered averaged 80% aortic flow rate, but this was extremely variable.

- 5 All neonatal/infant hearts arrested with AL solution recovered after 2 hr intermittent ischaemic arrest. Only 4 out o 7 hearts arrested with St Thomas solution recovered after 2 hr intermittent ischaemic arrest. In AL arrested hearts, heart rate and systolic pressure recovered to 90-100% of control values wherein St Thomas' hearts there was only 50-60% recovery. Aortic flow, 10 coronary flow and rate-pressure product recovered to 80% and above the controls in AL hearts and only about 50% in St Thomas hearts. Oxygen consumption in the AL hearts was 70-85% of controls and about 60% for the hearts arrested with St Thomas solution. It can be concluded that AL arrest provides superior protection during 2 hr arrest and recover in neonatal/infant 15 hearts.

Table 8

Characteristics of Neonatal Immature Rat Heart Arrest* Achieved by Adenosine/Lignocaine Cardioplegia and St Thomas Hospital No. 2

***(2 min Cardioplegia pulse repeated after 20 min of aortic clamping).**

Reperfusion afterload of 50 mmHg.

	Adenosine/ Lignocaine	St Thomas Hospital Solution No. 2	p
Arrest Time(s)	18.57 ± 3.72(7)	65.71* ± 12.71(7)	<0.05
Time to First Contraction	23.83	55.75*	<0.05
Following Reperfusion(s)	± 3.03(7)	±12.97(4)	
Time to Recover 50mmHg	165	270	ns
Aortic flow(s)	± 29.48(7)	± 83.5(4)	
Percentage of Hearts to Survive Reperfusion	100(7)	57*(4)	<0.05
Arrhythmia Occurrence (%)	14(7)	25(4)	ns

* Denotes Statistical Significance $p < 0.05$ using Students t-test

Table 9

Comparison of functional Recovery of Immature Rat Hearts After 2hr Ischaemic* Arrest With Adenosine/Lignocaine Cardioplegia or St Thomas Hospital Solution No. 2

*(2min cardioplegia doses delivered between 20min periods of aortic clamping)

Stable Perfusion Period							
	n	Heart Rate (bpm)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine + Lignocaine Cardioplegia	7	261.98 \pm 12.81	6.99 \pm 1.30	4.80 \pm 0.56	13.45* \pm 1.16	16579 \pm 853	4.60 \pm 0.52
St Thomas Hospital Solution No 2	7	239.96 \pm 19.52	4.43 \pm 1.05	4.29 \pm 0.76	9.95* \pm 1.01	15515 \pm 1149	5.39 \pm 0.61
							2 Hr Ischaemic Arrest with 2min Cardioplegia Delivered Every 20min

Table 9 cont.

After 15 min Reperfusion							
	n	Heart Rate (bpm)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	7	230.94	5.37	4.03	11.77	14046	4.71
+ Lignocaine		± 12.33	± 1.63	± 0.61	± 1.84	± 1297	± 0.33
Cardioplegia							
St Thomas	4	233.45	3.78	4.58	10.87	13818	4.36
Hospital		± 36.2	± 1.51	± 1.2	± 1.99	± 3103	± 0.67
Solution No. 2							

Table 9 cont.

After 30min Reperfusion							
	n	Heart Rate (bpm)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	7	235.39	6.67	4.09	12.45	14994	4.43
+ Lignocaine		± 8.99	± 1.58	± 0.68	± 1.71	± 709	± 0.24
Cardioplegia							
St Thomas	4	228.55	4.38	4.00	10.63	13522	4.14
Hospital		± 32.67	± 1.68	± 1.14	± 1.97	± 2912	± 0.69
Solution No. 2							

Table 9 cont.

After 60min Reperfusion							
	n	Heart Rate (bpm)	Aortic Flow (ml/min)	Coronary Flow (ml/min)	Cardiac Output (ml/min)	RP Product (mmHg/min)	MV02 (μ mol/min/g)
Adenosine	7	242.78	6	3.75	13.05	13272	4.13
+ Lignocaine		± 30.35	± 1.66	± 0.57	± 1.55	± 2643	± 0.62
Cardioplegia							
St Thomas	4	234.48	3.88	3.58	9.68	13910	4.02
Hospital		± 40.16	± 1.41	± 0.92	± 1.50	± 3262	± 0.75
Solution No 2							

EXAMPLE 4

Table 10 below shows that adenosine and lignocaine are effective in 1-2 day old neonatal pig heart cardioplegia. (2 hours of 2min pulses of cardioplegia administered between 20min periods of aortic clamping).

Table 10

<i>n</i>	Arrest Time (s)	Heart Rate Recovery (After 2hr Arrest*)
1	8	75%

EXAMPLE 5

Male Wistar rats (250g) were housed in a temperature and light-controlled room. Food and water were provided freely until the day before the experiment when the food was withheld and the rats were fasted overnight. The rats were anaesthetised with an intraperitoneal injection of pentobarbital (60mg kg⁻¹). Under anaesthesia, the rats were implanted with cannulas in the femoral vein and artery for adenosine and lignocaine (AL) administration and blood pressure measurement, respectively. A tracheotomy was performed and the rats were artificially ventilated with room air at 60 to 70 breaths/min. The chests of the rats were cut open and the left anterior descending (LAD) coronary artery located. A piece of suture was placed underneath LAD. After a 20min baseline period, LAD of the group of experimental rats were ligated for 30min and blood pressure and heart rate monitored. After 30 min of ischaemia, the ligature was released and the heart reperfused for 20 min. In the control rats, no AL was administered as shown in Figure 7. In the AL infusion 3 rats were used at three different doses of adenosine:

(1) 6.3 mg/ml adenosine + 12.6 mg/ml lignocaine infused at 1 ml/hr/300 g rat as shown in Figures 8 and 9;

(2) 3.15 mg/ml adenosine + 12.6 mg/ml lignocaine infused at 1 ml/hr/300 g rat as shown in Figure 10; and

(3) 1.6 mg/ml adenosine + 12.6 mg/ml lignocaine infused at 1 ml/hr/300 g rat as shown in Figures 11 and 12.

5 Compared to rats with 30 min ischaemia (no AL infusion) it was found that AL protected the heart in a dose dependent manner with the greatest protection occurring at the higher doses. As the dose of adenosine was halved, the protection was progressively lost. However, even in the worse case, the function of the heart was significantly better than with no AL alone. All hearts
10 in rats receiving AL recovered in rate and pressure.

Summary of Adenosine and lignocaine during a Heart Attack *in vivo*

During a 30 min heart attack or myocardial infarction (MI) in the rat model, Figure 7 shows that at 10 min blood pressure approaches zero and the
15 animal would be considered close to death. After 10 min, the heart recovers and blood pressure increases and is highly erratic from the ischaemic insult. This recovery is probably due to the recruitment of collateral circulation. In contrast, when a solution of adenosine and lignocaine is infused into the rat 5 min before occluding the coronary artery, no such fall in blood pressure is seen at 10 min
20 (Figure 8). Where the animal without receiving AL solution nearly died at 10 min, in the presence of AL solution the heart lowers its rate of contraction and misses only a few beats. Noteworthy, there was no irregular beating of the heart at 20 min of ischaemia. All hearts recovered to full function after AL infusion was stopped (Figure 9). It can be concluded that the heart in the
25 presence of AL solution was dramatically protected against a profound ischaemic insult elicited by occluding the coronary artery. The protective effect of the AL solution on the heart was related to the dose of adenosine. If the amount of adenosine was halved but the amount of lignocaine remained constant, more variability at 10 min and 20 is seen (Figure 10). If the amount of
30 adenosine was halved again, the protection was reduced further. In all cases

however, AL infused rats fully recovered haemodynamic function based on blood pressure and heart rate (Figure 12).

Two groups of rats undergoing a heart attack with and without a solution of AL were placed in a nuclear magnetic resonance (NMR) spectrometer and the metabolic data is shown in Figures 13 to 15. NMR non-invasively measures the changes in adenosine-triphosphate (ATP), phosphocreatine (PCr) and pH during 30 min of coronary artery occlusion. In a separate experiment on the bench, hearts were freeze-clamped at liquid nitrogen temperatures and glycogen and lactate were measured using routine enzymatic methods on neutralised tissue acid-extracts using a spectrophotometer. Major significant differences ($P < 0.05$) were seen in the hearts receiving AL solution during coronary artery occlusion. ATP remained between 90-100% of the control values in AL hearts compared to 60% in hearts receiving no AL (Figure 13). The same was shown for the high-energy phosphate store PCr, although greater percentage falls were shown in hearts with no AL (down to as low as 20% of pre-occlusion values) (Figure 14). In hearts receiving AL over the ischaemic period lactate, an end-product of anaerobic metabolism, increased 5-fold whereas lactate in hearts without AL increased over 20-fold (Figure 15). This was also supported by measuring the myocardial cell pH; greater decreases in pH (more acid) are seen in hearts not receiving AL solution. Noteworthy, in the first 10 min the pH fell only slight in AL hearts indicating that the myocardial cells in the presence of AL were more aerobic supported by the lower tissue lactate levels. The fuel glycogen was used in similar amounts by hearts with and without AL in the first 10 min but remained at about 60-70% of the pre-occlusion values in AL hearts compared to ischaemic hearts alone. It can be concluded from the metabolic data that coronary-occluded hearts receiving AL remained more aerobic than those hearts not receiving AL. Glycogen was a major source of fuel for each heart but the AL hearts preferentially regenerated their ATP from mitochondrial oxidative phosphorylation not from lactate production. This is wholly consistent with the functional data discussed above from changes in blood pressure and heart rate.

EXAMPLE 6

Arrest solutions were made with 200 μ M and 50 μ M of the local anaesthetics prilocaine, procaine and mepivacaine in Krebs-Henseleit having 10mM glucose at pH7.4. The results shown in Table 11 below are for 30min constant perfusion of cardioplegia at 70mmHg.

Table 11

	Adenosine + PRILOCAINE	Adenosine + PROCAINE	Adenosine + MEPIVACAINE
ARREST TIME	13s	21s	10.5s
1 st BEAT	1:13	1:45	0:36
AORTIC FLOW	3:12	3:35	3:40
RECOVERY			
5min AF%	67%	58%	39%

EXAMPLE 7

Arrest solutions were made with pinacidil dissolved in 0.05% dimethylsulfoxide (DMSO) (200 μ M) the local anaesthetics prilocaine, procaine, mepivacaine and lignocaine in Krebs-Henseleit solution. As shown in Table 12 below, pinacidil was found to be not as effective as adenosine.

Table 12

	Pinacidil + PRILOCAINE	Pinacidil + PROCAINE	Pinacidil + MEPIVACAINE	Pinacidil + LIGNOCAINE
Arrest Time	1:28	4:22s	0:41	1:49
1 st Beat	2:15	1:20	0:56	2:30
Aortic Flow	8:10	4:50	6:55	4:45
Recovery				
5min AF%	0%	25%	0%	70%
15min AF%	38%	57%	36%	71%

EXAMPLE 8

The addition of the ATP-potassium channel blocker, glibenclamide (20 μ M) and adenosine and lignocaine, delayed arrest times more than threefold from 26 sec (AL) to 76-120 sec (ALG) (n=2). Furthermore the slower recovery times and lower aortic flow (42-53%) in the presence of glibenclamide shows the importance of opening the KATP channels as a mode of arrest and protection afforded by AL. It can be concluded from these results that the ATP-potassium channel is an important target eliciting the arrest response from adenosine and lignocaine.

Table 13

	A/L + 20 μ M Glibenclamide (n=2)	A/L Alone (n=5)
Arrest Time	76-120s	26.s
1 st Beat	2:45-2:55 (min:s)	1min:37s
Aortic Flow	5:00-7:30 (min:s)	3min:51s
Recovery Time		
5min AF%	42-53%	84%

Claims

1. A method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or
5 agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof.
2. A method as claimed in claim 1, wherein the organ is either intact in the body of the subject or isolated.
3. A method as claimed in claim 1 or 2, wherein the organ is a circulatory
10 organ, respiratory organ, urinary organ, digestive organ, reproductive organ, neurological organ or somatic cell.
4. A method as claimed in claim 3, wherein the circulatory organ is a heart.
5. A method as claimed in claim 4, which is used to arrest, protect and/or preserve the heart during open-heart surgery, reduce heart damage before,
15 during or following cardiovascular intervention or protect those portions of the heart that have been starved of normal flow, nutrients and/or oxygen.
6. A method as claimed in any one of claims 1 to 5, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-
20 hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benzimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIC (Q-type), cyproheptadine HCl, dantrolene sodium (Ca^{2+}
25 release inhibitor), diltiazem HCl (L-type), flodipine, flunarizine HCl ($\text{Ca}^{2+}/\text{Na}^{+}$), fluspirilene (L-type), HA-1077 2HCl(1-(5 isoquinoliny sulphonyl) homo piperazine.HCl), isradipine, loperamide HCl, manoalide (Ca^{2+} release inhibitor), nicardipine HCl (L-type), nifedipine (L-type), niguldipine HCl (L-type), nimodipine (L-type), nitrendipine (L-type), pimozide (L- and T- type),
30 ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HCl (L-type), methoxy-verapamil HCl (L-type), YS-035 HCl (L-type)N[2(3,4-

dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethanamine HCl) and AV blockers.

7. A method as claimed in claim 6, wherein the AV blocker is adenosine.

8. A method as claimed in any one of claims 1 to 7, wherein the adenosine
5 receptor agonist is selected from N⁶-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl)ethyl]adenosine, 2-chloro-N⁶-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-
10 D-ribofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).

9. A method as claimed in any one of claims 1 to 8, wherein the local
15 anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mivacaine and Class 1B antiarrhythmic agents.

10. A method as claimed in claim 9, wherein the class 1B antiarrhythmic agent is lignocaine.

11. A method as claimed in any one of claims 1 to 10, wherein active
20 ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient.

12. A method as claimed in claim 11, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient is a buffer having a pH of about 6 to about 9.

25 13. A method as claimed in claim 11 or 12, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of potassium.

14. A method as claimed in claim 13, wherein the concentration of potassium is up to about 10mM.

15. A method as claimed in any one of claims 12 to 14, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Frenes solution, Hartmanns solution or Ringers-Lactate.
16. A method as claimed in any one of claims 11 to 15, wherein the
5 pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of magnesium.
17. A method as claimed in claim 16, wherein the concentration of magnesium is up to about 2.5mM.
18. A method as claimed in any one of claims 1 to 17, wherein the active
10 ingredients (i) and (ii) are administered together with another medicament.
19. A method as claimed in claim 18, wherein the medicament is dipyridamole or a clot-busting drug.
20. A method as claimed in claim 19, wherein the clot-busting drug is streptokinase.
- 15 21. A method as claimed in any one of claims 1 to 20, wherein the subject is a neonate/infant.
22. A method as claimed in any one of claims 4 to 21, wherein the administration in cardiovascular applications is achieved by mixing the active ingredients with the blood of the subject and/or a subject having a similar blood
20 type.
23. A method as claimed in any one of claims 1 to 22, wherein arrest is achieved by either continuous or intermittent delivery.
24. A method as claimed in any one of claims 1 to 23, wherein the arrest occurs at temperatures of about 15°C to about 37°C.
- 25 25. Use of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic in the manufacture of a medicament for arresting, protecting and/or preserving an organ.
26. A (i) potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic for use in arresting, protecting and/or
30 preserving an organ.

27. A method for arresting, protecting and/or preserving an organ which comprises adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ.
- 5 28. A pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.
29. A composition as claimed in claim 28, wherein the potassium channel opener or agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benzimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HCl (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIC (Q-type), cyproheptadine HCl, dantrolene sodium (Ca^{2+} release inhibitor), diltiazem HCl (L-type), flodipine, flunarizine HCl ($\text{Ca}^{2+}/\text{Na}^{+}$), fluspirilene (L-type), HA-1077 2HCl(1-(5 isoquinoliny) sulphonyl) homo piperazine.HCl), isradipine, loperamide HCl, manolide (Ca^{2+} release inhibitor), nicardipine HCl (L-type), nifedipine (L-type), nifedipine HCl (L-type), nimodipine (L-type), nitrendipine (L-type), pmozide (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HCl (L-type), methoxy-verapamil HCl (L-type), YS-035 HCl (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethanamine HCl) and AV blockers.
- 15 30. A composition as claimed in claim 29, wherein the AV blocker is adenosine.
31. A composition as claimed in claims 28 to 30, wherein the adenosine receptor agonist is selected from N^6 -cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N^6 -[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl)ethyl]adenosine, 2-chloro- N^6 -
- 20 25 30

cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-ribofuranosyl]-adenine (AB-MECA), ([IS-[1a,2b,3b,4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579), N⁶-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine 9APNEA) and cyclohexyladenosine (CHA).

32. A composition as claimed in claims 28 to 31, wherein the local anaesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mivacaine and Class 1B antiarrhythmic agents.

33. A composition as claimed in any one of claims 28 to 32 wherein the composition is a cardioplegic or cardioprotectant composition.

34. A composition as claimed in any one of claims 28 to 33, wherein active ingredients (i) and (ii) are administered together with a pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient.

35. A composition as claimed in claim 34, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient, is a buffer having a pH of about 6 to about 9.

36. A composition as claimed in claim 34 or 35, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of potassium.

37. A composition as claimed in claim 36, wherein the concentration of potassium is up to about 10mM.

38. A composition as claimed in any one of claims 35 to 37, wherein the buffer is Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Frenes solution, Hartmanns solution or Ringers-Lactate.

39. A composition as claimed in any one of claims 34 to 38, wherein the pharmaceutically acceptable carrier, diluent, adjuvant and/or excipient has low concentrations of magnesium.

40. A composition as claimed in claim 39, wherein the concentration of magnesium is up to about 2.5mM.

41. A composition as claimed in any one of claims 29 to 40, wherein the active ingredients (i) and (ii) are administered together with another medicament.

42. A composition as claimed in claim 41, wherein the medicament is
5 dipyridamole or a clot-busting drug.

43 A composition as claimed in claim 42, wherein the clot-busting drug is streptokinase.

1/15




Figure 1

2/15




Figure 2

3/15




Figure 3

4/15




Figure 4

5/15




Figure 5

6/15




Figure 6

7/15




Figure 7

8/15




Figure 8

9/15




Figure 9

10/15




Figure 10

11/15




Figure 11

12/15




Figure 12

13/15





Figure 13

14/15




Figure 14




Figure 15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00226

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : A01N 1/02		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA: (potassium channel openers or ion channel openers or potassium channel agonist or purinoceptor agonist) and (anesthetics); MEDLINE: (organ preservation solutions and anesthetics) or (linocaine and adenosine)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 432 053 (BERDYAEV ET AL.) 11 July 1995 whole document	1-5, 25-28
Y	SULTAN, I., et al., "Heart Preservation: Analysis of Cardioprotective Infusate Characteristics. Membrane Stabilization, Calcium Antagonism, and Protease Inhibition on Myocardial Viability: A Biochemical, Ultrastructural, Functional Study", Journal of Heart and Lung Transplantation, Vol. 11, No. 4, Part 1, July/August 1992, pages 607-18 whole document	1-7, 9-13, 25-29
Y	US 5 370 989 (STERN et al.) 6 December 1994 whole document	1-7, 9-13, 25-29
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 23 May 2000		Date of mailing of the international search report 09 JUN 2000
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer JAMIE TURNER Telephone No : (02) 6283 2071

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00226

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 145 771 (LEMASTERS et al.) 8 September 1992 whole document	1-7, 9-13, 25-29
Y	US 4 798 824 (BELZER et al.) 17 January 1989 whole document	1-7, 9-13, 25-29
Y	HICKS, M., et al., "ATP-Sensitive Potassium Channel Activation Mimics the Protective Effect of Ischaemic Preconditioning in the Rat Isolated Working Heart After Prolonged Hypothermic Storage", Clinical and Experimental Pharmacology and Physiology, Vol. 26, No. 1, 1999, pages 20-25 whole document	1-7, 9-13, 25-29

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00226

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
US	5 432 053	RU	2025973	WO	93/15604	AU	14580/92
US	5 370 989	US	5552267				
US	5 145 771						
US	4 798 824	AU	608744	CA	1282342	EP	237567
		WO	87/01940	US	4879283	US	4873230
		AU	609236	BE	1003362	CH	678912
		DE	3843958	FR	2625073	GB	2213362
		HU	49782	IT	1227916	JP	1246201
		NL	8803186	NZ	227516	PH	27182
		SE	8804661	ZA	8809683		

END OF ANNEX

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.